Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H13NO2 |
Molecular Weight | 167.205 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(CCN)=CC=C1O
InChI
InChIKey=DIVQKHQLANKJQO-UHFFFAOYSA-N
InChI=1S/C9H13NO2/c1-12-9-6-7(4-5-10)2-3-8(9)11/h2-3,6,11H,4-5,10H2,1H3
3-Methoxytyramine (3-MT) is a human trace amine that occurs as a metabolite of the neurotransmitter dopamine. It has been shown to act as an agonist of human TAAR1, and an inhibitor of mitochondrial respiration. 3-MT has garnered research interest for its potential links and implications to Parkinson's disease and other Neurological disorders.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20976142
Curator's Comment: CNS Active; but limited capacity to penetrate BBB.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q96RJ0 Gene ID: 134864.0 Gene Symbol: TAAR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20976142 |
700.0 nM [EC50] | ||
Target ID: GO:0005746 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15525332 |
19.6 mM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Postmortal accumulation of 3-methoxytyramine in brain. | 1974 |
|
Determination of urinary normetanephrine, metanephrine, and 3-methoxytyramine by liquid chromatography, with amperometric detection. | 1977 Jul |
|
Determination of catecholamines and their 3-O-methylated metabolites in urine by mass fragmentography with use of deuterated internal standards. | 1979 Mar |
|
Determination of catecholamines by radioenzymatic assay using ion-pair liquid chromatography. | 1981 Apr 10 |
|
Melanoma detection by enzyme-radioimmunoassay of L-dopa, dopamine, and 3-O-methyldopamine in urine. | 1981 Jan |
|
Postmortem accumulation of 3-methoxytyramine in the brain. | 1984 Aug 23 |
|
Extractive acylation and mass spectrometric assay of 3-methoxytyramine, normetanephrine, and metanephrine in cerebrospinal fluid. | 1985 Sep |
|
Increased monoamine metabolite concentrations and cholinesterase activities in cerebrospinal fluid of patients with acute stroke. | 1987 Dec |
|
Ketanserin reduces a particular monoamine pool in peripheral tissues. | 1989 Mar |
|
Analysis of S-nitroso-N-acetylpenicillamine effects on dopamine release in the striatum of freely moving rats: role of endogenous ascorbic acid and oxidative stress. | 2001 Feb |
|
Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis. | 2002 Jun |
|
Determination of catecholamines and metanephrines in urine by capillary electrophoresis-electrospray ionization-time-of-flight mass spectrometry. | 2002 Sep 5 |
|
Sources and significance of plasma levels of catechols and their metabolites in humans. | 2003 Jun |
|
Inhibitory phenolic amides on lipopolysaccharide-induced nitric oxide production in RAW 264.7 cells from Beta vulgaris var. cicla seeds. | 2003 Sep |
|
Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off. | 2004 Jun |
|
Assessment of O-methylated catecholamine levels in plasma and urine for diagnosis of autonomic disorders. | 2004 Nov 30 |
|
The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence. | 2004 Oct |
|
Metabolism of homovanillamine to homovanillic acid in guinea pig liver slices. | 2005 |
|
Enhanced dopamine uptake in the striatum following repeated restraint stress. | 2005 Sep 1 |
|
Isolation and identification of phase II enzyme-inducing agents from nonpolar extracts of green onion (Allium spp.). | 2006 Nov 1 |
|
Autologous bone marrow transplanation for extramedullary plasmacytoma presenting as adrenal incidentaloma. | 2009 May-Jun |
|
Generation and characterization of conditional heparin-binding EGF-like growth factor knockout mice. | 2009 Oct 14 |
|
Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands. | 2009 Oct 23 |
|
Further evidence for aberrant prefrontal salience coding in schizophrenia. | 2010 |
|
Low penetrance of a SDHB mutation in a large Dutch paraganglioma family. | 2010 Jun 11 |
|
Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice. | 2010 Jun 8 |
|
In utero exposure to a low concentration of diesel exhaust affects spontaneous locomotor activity and monoaminergic system in male mice. | 2010 Mar 23 |
|
Attenuation of circulatory shock and cerebral ischemia injury in heat stroke by combination treatment with dexamethasone and hydroxyethyl starch. | 2010 Oct 11 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20976142
Locomotor activity of DAT-KO and WT mice was measured in an Omnitech CCDigiscan. To assess effects of 3-MT in normal and TAAR1-KO mice, the animals were placed in the locomotor activity chamber and 30 min later various doses of 3-MT were administered i.c.v. over 4 minutes. After infusion, animals were put back into experimental chamber and behavior was monitored for 90 min after administration. 3-MT induced significant behavioral activation in DDD mice. Striatal tissue was collected from DDD mice treated with 36 µg of 3-MT 30 minutes after administration was analyzed for ERK activity. 3-MT caused a significant increase in the level of phosphorylated Erk2, thus indicating that certain receptor-mediated processes in striatal cells are affected by this treatment.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15525332
Mitochondria were isolated from whole brains of Sprague-Dawley rats. Mitochondria were suspended in 1 mL of incubation buffer containing 0.095MKCl, 0.075Mmannitol,0.025Msucrose, 0.005MKH2PO4, 0.020MTris-HCl, 0.001MEGTA, pH 7.4 (adjusted with KOH) at a final concentration of between 0.40 and 0.80 mg protein/mL. Malate and pyruvate were added to a final concentration of 10 mM. Oxygen consumption was carried out at 30°C in a closed chamber containing a Clark type oxygen electrode connected to a YSI model5300 oxygen monitor. Following a 10-minute incubation, resting conditions (no ADP) were monitored for 5 minutes, followed by the addition of ADP (0.25 mMfinal concentration) and measurement of active respiration. ADP depleted respiration was also monitored. Pre-incubation with the mitochondrial inhibitor 3-Methoxytyramine (3-MT) was carried out for15 min at 30°C prior to addition of ADP. Incubation with 3-MT was carried out in the dark for the first 10 minutes. IC50measurements represent the millimolar concentration of inhibitor required to inhibit 50% malate/pyruvate supported respiration compared with controls containing no inhibitor following a 15-min incubation at 30°C. 3-MT was found to inhibit brain mitochondrial respiration by MAO-dependent and -independent mechanisms. The IC50 of mitochondrial respiratory inhibition for 3-MT was determined to be 19.6 mM.
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
80156-3
Created by
admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
|
||
|
LOINC |
40409-5
Created by
admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
|
||
|
LOINC |
54343-9
Created by
admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
|
||
|
LOINC |
50140-3
Created by
admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
|
||
|
LOINC |
50139-5
Created by
admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
|
||
|
LOINC |
48381-8
Created by
admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
|
||
|
LOINC |
54344-7
Created by
admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
|
||
|
LOINC |
48380-0
Created by
admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
|
||
|
LOINC |
32618-1
Created by
admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C001746
Created by
admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
|
PRIMARY | |||
|
1669
Created by
admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
|
PRIMARY | |||
|
JCH2767EDP
Created by
admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
|
PRIMARY | |||
|
3-Methoxytyramine
Created by
admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
|
PRIMARY | |||
|
554-52-9
Created by
admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
|
PRIMARY | |||
|
1742513
Created by
admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
|
PRIMARY | |||
|
DTXSID40862189
Created by
admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
|
PRIMARY |
PARENT (METABOLITE INACTIVE)
SUBSTANCE RECORD